The US FDA has approved dupilumab for treating adults with prurigo nodularis, the first treatment approved for this indication.
MOA: Dupilumab (Dupixent), which inhibits the signaling of the interleukin 4 and interleukin 13 pathways, show significant improvements in both itchiness and lesion counts compared with placebo in adults with prurigo nodularis (PN).
Dose: 300 mg SC injection every 2 weeks after a loading dose.
Adverse effects: nasopharyngitis, conjunctivitis, herpes infection, muscle pain, diarrhea